欢迎来到天天文库
浏览记录
ID:55658167
大小:192.08 KB
页数:3页
时间:2020-05-23
《聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、昆明医科大学学报2014,35(2):100—101CN53—1221/RJournalofKunmingMedicalUniversity聚乙二醇干扰素()c一2a联合利巴韦林治疗慢性丙型肝炎的临床观察杨永锐”,李晖”,沈凌(1)昆明市第三人民医院,云南昆明650041;2)昆明医科大学公共卫生学院,云南昆明650500)[摘要]目的观察聚乙二醇干扰素一2a联合利巴韦林治疗慢性丙型肝炎的疗效和安全性.方法将106例慢性丙型肝炎患者随机分为2组,给予抗病毒治疗,实验组给予皮下注射聚乙二醇干扰素一2a180,每周1次;对照组给予皮下注射干扰素一lb5MIU,隔日1次,2组均按体重同时服用联合利巴
2、韦林900~1200rag,每天1次,疗程48周.分别在治疗前、治疗第4周、l2周、24周、治疗结束时、治疗结束后24周测定患者血清HCV—RNA水平,同时观察不良反应.结果实验组的快速病毒学应答率(RVR)为77.4%,完全早期病毒学应答率(cEVR)为83.0%,治疗结束应答率(ETVR)为90.6%,治疗结束后随访24周持续应答率(SVR)为84.9%,明显优于对照组.结论聚乙二醇干扰素一2a联合利巴韦林治疗慢性丙型肝炎具有良好的抗病毒疗效,安全性较好.[关键词]慢性丙型肝炎;聚乙二醇干扰素t一2a;利巴韦林;疗效;安全性[中图分类号]R512.6[文献标识码]A[文章编号]2095-6
3、10X(2014)02—010o一03ClinicalObservationofChronicHepatitisCTreatedby-PegylatedInterferonAlpha-2aPlusRibavirinYANGYong-rui”,LIHui”,SHENLing2】(1)Dept.ofHepatology,The3rdPeople’sHospitalofKunming,KunmingYunnan650041;2)SchoolofPublicHealth,KunmingMedicalUniversity,KunmingYunnan650500,China)[Abstract]Objec
4、tiveToobservetheeficacyandsafetyofpegylatedinterferonapha-2acombinedwithribavirininthetreatmentofchronichepatitisC.MethodsOnehundredandsixpatientswithchronichepatitisCweredividedinto2groupsrandomly.Patientsintheobservationgroupweretreatedwithpegylatedinterferonalpha-2a,andpatientsinthecontrolgroupwe
5、retreatedwithinterferonalpha-lb.Allpatientsweregivenribavirinaccordingtotheweight,andthetreatmentcoursewas48weeks.HCV—RNAwastestedbeforetreatment,4weeks,12weeksand24weeksafterthestartoftreatment,endoftreatment,24weeksaftertheendoftreatment.Theadversereactionswerealsoobserved.ResultsIntheobservationg
6、roup,therapidvirologicalresponse(RVR)was77.4%,thecompleteearlyvirologicalresponse(cEVR)was83.0%,theendtreatmentvirologicalresponse(ETVR)was90.6%,thesustainedvirologicalresponse(SVR)of24weeksaftertheendoftreatmentwas84.9%.andtheseratesweresignificantlyhigherthanthecontrolgroup.Allpatientsreceivedthew
7、holecourseoftreatment.CondusionTreatmentofchronichepatitisCwithpegylatedinterferonapha一2acombinedwithribaviriniseffectiveandsafe.[Keywords]ChronichepatitisC;Pegylatedinterferonalpha-2a;Ribavirin;Efica
此文档下载收益归作者所有